Article

Synergistic Effect of PARP Inhibitor and BRD4 Inhibitor in Multiple Models of Ovarian Cancer

2021-12-28

Abstract excerpt

<h4>Background: </h4> Ovarian cancer has the highest fatality rate among patients with gynaecological tumours. Current therapies including poly-ADP ribose polymerase (PARP) inhibitors have limitations due to the frequent recurrence of ovarian cancer after treatment and resistance to therapy. <h4>Methods: </h4> In this study, we used multiple models with different genetic backgrounds to investigate the potential sy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4cd10aa3-fdb3-56c5-beb6-4853b00bbeb4
DOI: 10.21203/rs.3.rs-1147194/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Synergistic Effect of PARP Inhibitor and BRD4 Inhibitor in Multiple Models of Ovarian CancerDOI 10.21203/rs.3.rs-1147194/v1Read

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian CancerSemantic proximity Read

Preclinical models to study the biology and therapy of ovarian cancerSemantic proximity Read

PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair PathwaySemantic proximity Read

MicroRNA320e augments the synthetic lethality of olaparib by regulating homologous recombination repair via PI3K-AKT-mTOR pathwaySemantic proximity Read

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity Read

Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.Semantic proximity Read

Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancerSemantic proximity Read

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity Read

Combination of olaparib and savolitinib overcomes olaparib-resistance in epithelial ovarian cancer modelsSemantic proximity Read

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.Semantic proximity Read

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomasSemantic proximity Read

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Semantic proximity Read